144 related articles for article (PubMed ID: 10601384)
1. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.
Bischoff ED; Heyman RA; Lamph WW
J Natl Cancer Inst; 1999 Dec; 91(24):2118. PubMed ID: 10601384
[TBL] [Abstract][Full Text] [Related]
2. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
Yen WC; Prudente RY; Lamph WW
Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
[TBL] [Abstract][Full Text] [Related]
4. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
Agarwal VR; Bischoff ED; Hermann T; Lamph WW
Cancer Res; 2000 Nov; 60(21):6033-8. PubMed ID: 11085524
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
Gottardis MM; Bischoff ED; Shirley MA; Wagoner MA; Lamph WW; Heyman RA
Cancer Res; 1996 Dec; 56(24):5566-70. PubMed ID: 8971154
[TBL] [Abstract][Full Text] [Related]
6. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
Kong G; Kim HT; Wu K; DeNardo D; Hilsenbeck SG; Xu XC; Lamph WW; Bissonnette R; Dannenberg AJ; Brown PH
Cancer Res; 2005 Apr; 65(8):3462-9. PubMed ID: 15833882
[TBL] [Abstract][Full Text] [Related]
7. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Lubet RA; Boring D; Steele VE; Ruppert JM; Juliana MM; Grubbs CJ
Cancer Prev Res (Phila); 2009 Feb; 2(2):161-7. PubMed ID: 19196723
[TBL] [Abstract][Full Text] [Related]
8. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.
Kim HT; Kong G; Denardo D; Li Y; Uray I; Pal S; Mohsin S; Hilsenbeck SG; Bissonnette R; Lamph WW; Johnson K; Brown PH
Cancer Res; 2006 Dec; 66(24):12009-18. PubMed ID: 17178900
[TBL] [Abstract][Full Text] [Related]
9. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.
Cohen LA; Pittman B; Wang CX; Aliaga C; Yu L; Moyer JD
Cancer Res; 2001 Dec; 61(24):8683-8. PubMed ID: 11751385
[TBL] [Abstract][Full Text] [Related]
10. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
11. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
Klopper JP; Sharma V; Berenz A; Hays WR; Loi M; Pugazhenthi U; Said S; Haugen BR
Mol Cancer; 2009 Mar; 8():16. PubMed ID: 19267912
[TBL] [Abstract][Full Text] [Related]
12. Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.
Woditschka S; Haag JD; Waller JL; Monson DM; Hitt AA; Brose HL; Hu R; Zheng Y; Watson PA; Kim K; Lindstrom MJ; Mau B; Steele VE; Lubet RA; Gould MN
Cancer Res; 2006 Jul; 66(13):6884-91. PubMed ID: 16818667
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention by melatonin and combined melatonin-tamoxifen therapy of second generation nitroso-methylurea-induced mammary tumours in rats.
Kothari A; Borges A; Kothari L
Eur J Cancer Prev; 1995 Dec; 4(6):497-500. PubMed ID: 8580786
[TBL] [Abstract][Full Text] [Related]
14. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Brown PH; Subbaramaiah K; Salmon AP; Baker R; Newman RA; Yang P; Zhou XK; Bissonnette RP; Dannenberg AJ; Howe LR
Cancer Prev Res (Phila); 2008 Aug; 1(3):208-14. PubMed ID: 19138958
[TBL] [Abstract][Full Text] [Related]
15. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Yen WC; Lamph WW
Mol Cancer Ther; 2005 May; 4(5):824-34. PubMed ID: 15897247
[TBL] [Abstract][Full Text] [Related]
16. 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.
Grubbs CJ; Hill DL; Bland KI; Beenken SW; Lin TH; Eto I; Atigadda VR; Vines KK; Brouillette WJ; Muccio DD
Cancer Lett; 2003 Nov; 201(1):17-24. PubMed ID: 14580682
[TBL] [Abstract][Full Text] [Related]
17. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH
Cancer Res; 2002 Nov; 62(22):6376-80. PubMed ID: 12438218
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
Gamage SD; Bischoff ED; Burroughs KD; Lamph WW; Gottardis MM; Walker CL; Fuchs-Young R
J Pharmacol Exp Ther; 2000 Nov; 295(2):677-81. PubMed ID: 11046105
[TBL] [Abstract][Full Text] [Related]
19. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis.
Orendas P; Kubatka P; Kajo K; Stollarova N; Kassayova M; Bojkova B; Pec M; Nosal V; Kiskova T; Zihlavnikova K; Karsnakova R
Neoplasma; 2012; 59(4):469-74. PubMed ID: 22489703
[TBL] [Abstract][Full Text] [Related]
20. Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Hilakivi-Clarke L; Wärri A; Bouker KB; Zhang X; Cook KL; Jin L; Zwart A; Nguyen N; Hu R; Cruz MI; de Assis S; Wang X; Xuan J; Wang Y; Wehrenberg B; Clarke R
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27609189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
